EP3402456A1 - Émulsion eau-dans-huile - Google Patents

Émulsion eau-dans-huile

Info

Publication number
EP3402456A1
EP3402456A1 EP17700351.4A EP17700351A EP3402456A1 EP 3402456 A1 EP3402456 A1 EP 3402456A1 EP 17700351 A EP17700351 A EP 17700351A EP 3402456 A1 EP3402456 A1 EP 3402456A1
Authority
EP
European Patent Office
Prior art keywords
skin
emulsion
water
oil emulsion
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17700351.4A
Other languages
German (de)
English (en)
Inventor
Christoph Abels
Ulrich Knie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr August Wolff GmbH and Co KG Arzneimittel
Original Assignee
Dr August Wolff GmbH and Co KG Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr August Wolff GmbH and Co KG Arzneimittel filed Critical Dr August Wolff GmbH and Co KG Arzneimittel
Publication of EP3402456A1 publication Critical patent/EP3402456A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/596—Mixtures of surface active compounds

Definitions

  • the present invention relates to a water-in-oil emulsion and its use as a skin care product, in particular as a cosmetic and as a (dermatological) drug especially for the elderly skin.
  • the pH of the skin is crucial for the physiological function of the skin. It is known that the pH of older as well as diseased skin is increased compared to the young and healthy skin (ie the acidity on the skin surface and / or in the stratum corneum is reduced) and thus the physiological skin functions are impaired can. To address this problem, it has been proposed to formulate skin care products for the lower skin with a lower pH. It is believed that this will normalize the age-related increase in skin pH and maintain physiological skin function (Schreml et al., EMJ Dermatol 2014, 2: 86-94). In addition, as the older skin loses moisture more easily than young skin, moisturizing ingredients are added to skin care products for the aging skin to help prevent dehydration or dehydration of the skin.
  • a particularly suitable measure is the formulation of the products in the form of water-in-oil emulsions (W / O), since these generally have a significantly longer moisture-absorbing effect in the skin than oil-in-water emulsions ( O / W) (Daniels et al., Galenics der Dermatika - Basics, Properties, Release, J. Dtsch Dermatol Ges 2007; 5: 367-383).
  • W / O emulsions generally have some disadvantages over O / W emulsions. Thus, they theoretically release the protons (H + ) in the inner water phase and ultimately influencing the pH of the skin slower than O / W emulsions in which the protons are in the outer / continuous phase. Consequently, for the above-mentioned potential lower pH skin care products for the treatment of the aging skin, where rapid and significant lowering of the pH is desired, an O / W emulsion should be significantly better than a W / O emulsion. In addition, the W / O emulsions are in the Compared to O / W formulations usually less stable, especially at low pH.
  • the problem lies among other things in the insufficient stability of the conventional emulsifier systems under acidic conditions.
  • Many emulsifiers are not resistant to hydrolysis at low pH values, which, on the one hand, reduces the emulsifier action and, on the other hand, can give rise to undesirable by-products.
  • the object on which the present invention is based was therefore to provide a W / O emulsion which is stable in the acidic pH range and which effectively restores the skin functions which are disturbed by age or disease.
  • the present invention relates to a water-in-oil emulsion (also commonly referred to as W / O emulsion) containing a disperse (or inner) water phase, a continuous (or external) oil phase and a specific emulsifier system.
  • An essential constituent of the emulsion according to the invention is furthermore a cc-hydroxy-C 2 -C 6 -carboxylic acid, which, owing to its solubility, is predominantly present in the water phase and which adjusts the pH of the emulsion to from 1 to 5.
  • the specific The emulsifier system comprises essentially three components, namely polyglyceryl-3-polyricinoleate, sorbitan oleate and sucrose polystearate and derivatives thereof.
  • the W / O emulsion according to the invention exhibits extremely good stability at low pH values, which is attributed to the specific emulsifier system.
  • the pH value can be effectively lowered both on the skin (pHss) and in the stratum corneum (pH sc ) with the W / O emulsion according to the invention.
  • the W / O emulsion according to the invention permits the effective restoration of the physiological properties (such as the epidermal barrier functions and barrier integrity), in particular of older and / or diseased skin, in which the acidity on the skin surface and / or in the stratum corneum is reduced.
  • the water phase of the W / O emulsion according to the invention comprises mainly water as solvent and optionally further water-soluble / hydrophilic auxiliary solvents, such as short-chain alcohols (for example ethanol, propanol or glycerol).
  • water is the only solvent in the water phase.
  • the proportion of the water phase ie, only the solvent without any further dissolved therein ingredients such as cc-hydroxy-C2-C ö -carboxylic acid
  • is present in the total W / O type emulsion ranges preferably from 50 to 80 wt.%, Particularly preferably from 60 to 70% by weight, in each case based on the total weight of the emulsion.
  • the oil phase of the W / O emulsion according to the invention may in principle contain all lipophilic constituents which are known to the person skilled in the art from conventional W / O emulsions. These include, among others, the glycerides (mono-, di- and triglycerides), fatty alcohols, fatty acid esters, hydrocarbons, silicone oils and others synthetic oils and fats.
  • suitable examples may be mentioned various vegetable oils and vegetable fats, especially hydrogenated vegetable oils (such as olive oil or sunflower seed oil), long-chain hydrocarbons (such as paraffin, petrolatum, ceresin, ozokerite or isohexadecane) or fatty acid esters (such as cetearyl isononanoate, ethylhexyl stearate, decyl oleate, isopropyl myristate, isopropyl palmitate, glyceryl stearate) and mixtures thereof.
  • Suitable oil phases can be selected by the skilled person depending on the desired product form from the known materials.
  • the oil phase preferably comprises isohexadecane, particularly preferably in combination with one or more fatty acid esters (such as cetearyl isononanoate, ethylhexyl stearate and / or decyl oleate) and / or one or more vegetable oils or vegetable fats (such as hydrogenated vegetable oils) and / or synthetic oils or synthetic oils Fats (such as dicaprylyl ether).
  • fatty acid esters such as cetearyl isononanoate, ethylhexyl stearate and / or decyl oleate
  • vegetable oils or vegetable fats such as hydrogenated vegetable oils
  • synthetic oils or synthetic oils Fats such as dicaprylyl ether
  • the proportion of the oil phase (ie only the solvent, without any further dissolved constituents) in the total W / O emulsion preferably ranges from 10 to 30% by weight, more preferably from 15 to 25% by weight, most preferably from 18 to 20 % By weight, in each case based on the total weight of the emulsion.
  • the amount alone of isohexadecane in the oil phase is preferably 1 to 10% by weight, preferably 5 to 8% by weight, in each case based on the total weight of the emulsion.
  • the W / O emulsion according to the invention also contains a -hydroxy-C 2 -C 6 -carboxylic acid.
  • the W / O emulsion according to the invention has a pH of from 1 to 5, preferably from greater than 1 to less than 5, particularly preferably from 2 to 5, very particularly preferably from 2.5 to 4.5 and even more preferably from 3.5 to 4.5.
  • the pH is most preferably 4. In these pH ranges of the emulsion according to the invention, the best results in terms of a rapid and significant lowering of the pH on both the treated skin and in the stratum corneum with maximum stability of W / O Emulsion can be achieved.
  • the hydroxy-C 2 -C ö -carboxylic acid according to the invention is preferably a fruit acid.
  • glycolic acid This is in particular selected from the group consisting of glycolic acid, milk acid, tartaric acid, citric acid, ascorbic acid, malic acid, and mixtures thereof. Particularly preferred is glycolic acid. If the chain length exceeds C6, there is a markedly reduced penetration of the acid into the stratum corneum, whereby the pH-lowering effect of the W / O emulsion on and in the skin becomes insufficient.
  • the amount of cc-hydroxy-C 2 -C 6 -carboxylic acid in the W / O emulsion can be easily adjusted by the skilled person according to the desired pH. It is preferably 0.5 to 3.0 wt.%, Preferably 1.0 to 2.0 wt.%, CC-hydroxy-C 2 -C 6 - carboxylic acid based on the total weight of the emulsion.
  • the W / O emulsion according to the invention may further contain a basic pH adjusting agent, preferably ammonium hydroxide.
  • a basic pH adjusting agent preferably ammonium hydroxide. The amount depends on the exact desired pH of the emulsion and can be adjusted accordingly by the skilled person.
  • a further constituent of the W / O emulsion according to the invention is the specific emulsifier system, which surprisingly ensures the high stability of the emulsion even at low pH values and at the same time after application of the emulsion to the skin the rapid and marked reduction in the pH the skin and in the stratum corneum.
  • the emulsifier system essentially comprises polyglyceryl-3-polyricinoleate, sorbitan oleate and sucrose polystearate.
  • the invention also includes their derivatives. These three components are known substances in their own right and are commercially available as such.
  • Polyglyceryl-3-polyricinoleate (also polyglycerol polyricinoleate; PGPR; E 476; Dermofeel® PR) is a carboxylic acid ester of an oligomeric glycerol with polymeric ricinoleic acid.
  • Sorbitan oleate also called sorbitan monooleate, SPAN 80
  • SAcrose polystearate is a sucrose fatty acid polyester of stearic acid.
  • the W / O emulsion according to the invention preferably contains 1.0 to 5.0% by weight of polyglyceryl-3-polyricinoleate, 2.0 to 10.0% by weight of sorbitan oleate and 0.5 to 3.0% by weight of sucrose polystearate , in each case based on the total weight of the emulsion.
  • the emulsion according to the invention particularly preferably contains 1.0 to 2.0% by weight of polyglyceryl-3-polyricinoleate, 3.0 to 5.0% by weight of sorbitan oleate and 1.0 to 1.5% by weight of sucrose polo. lystearate, in each case based on the total weight of the emulsion.
  • the emulsion according to the invention most preferably contains 1.0 to 1.5% by weight of polyglyceryl-3-polyricinoleate, 3.0 to 3.5% by weight of sorbitan oleate and 1.0 to 1.5% by weight of sucrose polystearate, in each case based on the total weight of the emulsion.
  • the weight ratio of polyglyceryl-3-polyricinoleate: sorbitan oleate: sucrose polystearate is preferably (1.0 to 1.5) :( 3.0 to 3.5) :( 1.0 to 1.5), especially 1 , 5: 3.5: 1.0.
  • the effects according to the invention with regard to stability and pH reduction on the skin and in the stratum corneum are achieved particularly clearly in the preferred quantity ranges. This is surprising since the amounts are low compared to conventionally used emulsifiers. Furthermore, it was also not foreseeable that with the preferred ratios of the three constituents of the emulsifier system, a particularly high stability can be achieved with simultaneously effective lowering of the pH of the skin.
  • the emulsifier system preferably consists of polyglyceryl-3-polyricinoleate, sorbitan oleate and sucrose polystearate, ie the W / O emulsion according to the invention preferably contains no further emulsifier apart from these three constituents.
  • the W / O emulsions of the invention may also contain common medical and cosmetic additives. These include in particular antioxidants, preservatives, stabilizers, emollients and perfume. Antioxidants are for example tocopherol or tocopherol acetate, in particular tocopherol. Stabilizers include, for example, magnesium sulfate, acrylate polymers, carbomers, starches, and xanthan gum. Suitable emollients are alkyl palmitate compounds (e.g., isopropyl palmitate) as well as paraffin and isoparaffins. Also included may be buffer systems such as citric acid and sodium citrate.
  • antioxidants include in particular antioxidants, preservatives, stabilizers, emollients and perfume.
  • Antioxidants are for example tocopherol or tocopherol acetate, in particular tocopherol.
  • Stabilizers include, for example, magnesium sulfate, acrylate polymers, carbomers, starches,
  • the fiction, contemporary W / O emulsion can be prepared by means of customary for W / O emulsions production process.
  • the oil phase and the water phase can be heated independently and then mixed together.
  • the other components ie, the emulsifier, the east cc hydroxy-C2-C carboxylic acid and, if present, the other additives
  • the two phases can also be mixed before the other ingredients are added.
  • the emulsifier system is added prior to mixing the oil phase, and the hydroxy-C2- C6 carboxylic acid is usually added to the water phase.
  • Temperatures typical for the preparation are 40 to 95 ° C, preferably 80 to 90 ° C.
  • the mixing is carried out in a homogenizer usually within 5 to 25 minutes at a stirring speed of 300 to 2000 U / min. Subsequently, the emulsion is cooled to room temperature.
  • the W / O emulsion according to the invention can be used as a medicament, preferably as a dermatological agent, as a medical product and / or as a cosmetic.
  • the use according to the invention leads to a marked improvement in the epidermal barrier functions and the epidermal barrier integrity, to improve the appearance of the skin and to increase the moisture content of the skin. This is accompanied by an increase in the cohesion of the stratum corneum and the homeostasis of the skin barrier and finally results in an improved protection against infections (microbial diseases).
  • the diseases are preferably microbial skin infections, skin inflammations, rough skin, dry skin, skin irritations, itching, pruritus, allergies, psoriasis, psoriatic arthritis, eczema, scleroderma, atopic dermatitis, contact dermatitis, systemic lupus erythematosus, alopecia areata, acne and Susceptibility to contact allergies.
  • the non-therapeutic (i.e., cosmetic) use particularly includes the treatment of cosmetic indications of the skin, especially selected from rough skin, dry skin, skin irritation, itching and pruritus, as well as the prevention of skin infections and the reduction of susceptibility to contact allergies.
  • the fiction, contemporary W / O emulsion may be present in various medical (dermatological) and / or cosmetic product forms. Basically, it is suitable for rinse-off or leave-on products. Preferred are leave-on products. Egg- A suitable product form is, for example, a cream, lotion, ointment, make-up, mascara or lipstick, in particular a face cream and a body lotion.
  • the preferred application of the W / O emulsion according to the invention depends on the specific product form and the medical or cosmetic indication to be treated. Particularly preferred is the topical application in particular to the hair, the skin and / or the mucous membranes, most preferably on the (facial) skin.
  • the frequency of use depends on the type and severity of the indication.
  • the W / O emulsion is applied once a week to several times a day, and more preferably once a day to several times a day (for example, twice or three times a day).
  • a W / O emulsion in the form of a pH 4 cream was prepared from the following ingredients.
  • the preparation was carried out as follows: The constituents of the oil phase including the emulsifier system (ie polyglyceryl-3-polyricinoleate, sorbitan oleate, cetearyl isononanoate, isohexadecane, dicaprylyl ether, sucrose polystearate, hydrogenated vegetable oil, tocopherol (70%)) were placed in a heatable container heated at 85 ° C, melted and mixed. In the purified water, the remaining ingredients were dissolved, except for the perfume, and the water phase heated to 85 ° C. The water phase was added to the oil phase, followed by homogenization and cooling. The perfume was finally added at 45 ° C.
  • the emulsifier system ie polyglyceryl-3-polyricinoleate, sorbitan oleate, cetearyl isononanoate, isohexadecane, dicaprylyl ether, sucrose polystearate, hydrogenated vegetable oil, tocop
  • a W / O emulsion in the form of a pH 4 lotion was prepared from the following ingredients.
  • the preparation was carried out as follows: The constituents of the oil phase including the emulsifier system (ie polyglyceryl-3-polyricinoleate, sorbitan oleate, ethylhexyl stearate, isohexadecane, decyl oleate, sucrose polystearate, tocopherol (70%)) were heated in a heatable container at 85.degree , melted and mixed. In the purified water, the remaining ingredients were dissolved, except for the perfume, and the water phase heated to 85 ° C. The water phase was added to the oil phase, followed by homogenization and cooling. The perfume was finally added at 45 ° C.
  • the emulsifier system ie polyglyceryl-3-polyricinoleate, sorbitan oleate, ethylhexyl stearate, isohexadecane, decyl oleate, sucrose polystearate, tocopherol (
  • An O / W emulsion in the form of a pH 4 cream was prepared from the following ingredients.
  • the preparation was carried out as follows: The components of the oil phase (i.e., PPG-15-stearyl ether, steareth-2, isohexadecane, steareth-21, cetearyl alcohol, dimethicone, stearic acid) were heated in a heatable container at 70 ° C, melted and mixed. The remaining constituents were dissolved or swollen in the purified water (xanthan gum) and the water phase was heated to 70.degree. The fat phase was added to the water phase, followed by homogenization and cooling.
  • the components of the oil phase i.e., PPG-15-stearyl ether, steareth-2, isohexadecane, steareth-21, cetearyl alcohol, dimethicone, stearic acid
  • the W / O emulsion of Example 2 and the O / W emulsion of Example 3 were subjected to a kinetic study. Twelve subjects in the middle age of 65 years (+/- 5 years) were applied the two test emulsions on inner sides of the forearms in an amount of 40 ⁇ each on an area of about 20 cm and distributed with the finger. Thereafter, the pH of the skin (B: treatment with Example 2, C: treatment with Example 3, A: untreated skin) was measured time-dependently using a Skin pH Meter PH 900 PC (Courage & Khazaka, Cologne, Germany). The pH-wet of untreated skin was used as a comparison.
  • the W / O emulsions according to the invention not only have excellent stability at low pH values, but can also rapidly and distinctly lower the pH of the skin - and unexpectedly faster than a corresponding O / M. W emulsion.
  • the W / O emulsions according to the invention can rapidly and effectively restore the skin functions which are impaired due to age or illness, and are therefore outstandingly suitable for the medical and cosmetic treatment of the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une émulsion eau-dans-huile et son utilisation comme produit de soin pour la peau, en particulier comme produit cosmétique et comme médicament (dermatologique) pour la peau âgée. Cette émulsion contient une phase aqueuse dispersée/interne comprenant un acide α-hydroxy-C2-C6-carboxylique, une phase huileuse continue/externe et un système émulsifiant qui comprend du polyglycéryl-3-polyricinoléate, du monooléate de sorbitane et du polystéarate de saccharose, l'émulsion présentant une valeur de pH de 1 à 5.
EP17700351.4A 2016-01-15 2017-01-13 Émulsion eau-dans-huile Withdrawn EP3402456A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16151515 2016-01-15
PCT/EP2017/050619 WO2017121831A1 (fr) 2016-01-15 2017-01-13 Émulsion eau-dans-huile

Publications (1)

Publication Number Publication Date
EP3402456A1 true EP3402456A1 (fr) 2018-11-21

Family

ID=55168197

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17700351.4A Withdrawn EP3402456A1 (fr) 2016-01-15 2017-01-13 Émulsion eau-dans-huile

Country Status (8)

Country Link
US (1) US20190021961A1 (fr)
EP (1) EP3402456A1 (fr)
JP (1) JP2019501934A (fr)
KR (1) KR20180101378A (fr)
CN (1) CN108463206A (fr)
CA (1) CA3010544A1 (fr)
RU (1) RU2018128002A (fr)
WO (1) WO2017121831A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3641725A1 (fr) 2017-06-23 2020-04-29 The Procter and Gamble Company Composition et procédé permettant d'améliorer l'aspect de la peau
GB2560209B (en) * 2017-07-28 2020-02-19 Alchemy Ingredients Ltd High internal phase emulsions
JP7063703B2 (ja) * 2018-04-20 2022-05-09 ミヨシ油脂株式会社 乳化物の安定化方法および乳化物とそれを用いたエマルション燃料
DE102018115270B4 (de) * 2018-06-26 2022-07-14 Vinederm GmbH Zubereitung als Gel und Pflaster zur topischen Behandlung von Haut- und/oder Nagelerkrankungen
CN112437657A (zh) 2018-07-03 2021-03-02 宝洁公司 处理皮肤状况的方法
RU2714763C1 (ru) * 2018-11-08 2020-02-19 Генетик Диагностикс Энд Терапи 21 Лтд Генотерапевтический ДНК-вектор для таргетной генной терапии, способ его получения (варианты), штамм для его производства, способ его получения
KR102644391B1 (ko) * 2018-11-29 2024-03-07 (주)아모레퍼시픽 안정도가 개선된 유중수형 화장료 조성물
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
JP2023528616A (ja) 2020-06-01 2023-07-05 ザ プロクター アンド ギャンブル カンパニー ビタミンｂ３化合物の皮膚への浸透を改善する方法
WO2023056278A1 (fr) * 2021-09-29 2023-04-06 Love Sun Body Ip Holdings Llc Compositions d'écran solaire pour corps et visage
DE102022207466A1 (de) * 2022-07-21 2024-02-01 Beiersdorf Aktiengesellschaft Verfahren zur Herstellung einer kosmetischen Wasser-in-Öl-Emulsion aus einer Glycerin-in-Öl-Emulsion
KR102627686B1 (ko) 2023-08-17 2024-01-24 코스맥스 주식회사 윤기 개선 효과가 있고 눈 입자와 같은 외관을 띄는액정 크림 화장료 조성물 및 이의 제조 방법

Also Published As

Publication number Publication date
RU2018128002A (ru) 2020-02-18
CA3010544A1 (fr) 2017-07-20
RU2018128002A3 (fr) 2020-02-18
JP2019501934A (ja) 2019-01-24
WO2017121831A1 (fr) 2017-07-20
US20190021961A1 (en) 2019-01-24
CN108463206A (zh) 2018-08-28
KR20180101378A (ko) 2018-09-12

Similar Documents

Publication Publication Date Title
EP3402456A1 (fr) Émulsion eau-dans-huile
DE602005002844T3 (de) Umkehremulsionszusammensetzung mit calcitriol und clobetasol-17-propionat und ihre kosmetische und dermatologische verwendung
EP0037011B1 (fr) Bases pour onguents à utilisation dermatologique et cosmétique
WO2007118653A2 (fr) Nanoparticules contenant de la nicotine et/ou de la cotinine, dispersions et leur utilisation
EP1937224A2 (fr) Produits pour le soin de la peau
DE102015222073A1 (de) Kosmetischer Make-Up Entferner mit verbesserter Hautbefeuchtung
DE69912760T2 (de) Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln
EP1839645B1 (fr) Emulsions cosmétiques ou dermatologiques comportant du licochalcone A ou un extrait comprenant du licochalcone A à partir de radix glycyrrhizae inflatae
DE69738034T2 (de) Topische Anwendung von Vitamin E Ester
EP0804150B1 (fr) Lotions contenant des derives d'acide gras
DE102005008299A1 (de) Universalpflegecreme
DE202016000224U1 (de) Wasser-in-Öl-Emulsion
DE19618809C1 (de) Kosmetisches Mittel
DE60306584T2 (de) Verwendung eines 7-oxidierten DHEA-Derivats zur Behandlung von trockener Haut
EP2399648B1 (fr) Composition cosmétique et son utilisation
EP0620000A3 (fr) Utilisation cosmétique et/ou pharmaceutique des N-acylalcanolamines
DE102012213935A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Harnstoff und einem Gehalt an Licochalcon A oder einem wäßrigen Extrakt aus Radix Glycyrrhizae inflatae, enthaltend Licochalcon A
WO2013135854A1 (fr) Produits cosmétiques pour peaux matures
EP1503729B1 (fr) Composition et son utilisation comme formulation pharmaceutique ou cosmetique pour application externe
EP2095807A1 (fr) Crème contre la cellulite et les tâches de rousseur
DE202022001251U1 (de) Pharmazeutisches Hautpflegemittel
EP0606590A1 (fr) Composition pharmaceutique et/ou cosmétique contenant des N-acylalcanolamines et des N-acylphospho- ou lysophospholipides
DE19649287A1 (de) Konservierungsmittel
DE19635359C2 (de) Lotion zur Körperpflege
EP3952822A1 (fr) Composition destinée à une application topique sur la peau

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180813

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1256326

Country of ref document: HK

17Q First examination report despatched

Effective date: 20190904

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603